Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gentamicin for Pharyngeal Gonorrhea
NCT03632109Phase 3Terminated
- Sponsor
- University of Washington
- Start
- Sep 2018
- Primary completion
- Mar 2019
- Modality
- Nanoparticles, Implantable Devices, Transdermal Patches
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gentamicin in Pharyngeal gonorrhea (PGC), sponsored by University of Washington. Primary endpoint: Percentage of Persons With Pharyngeal Gonorrhea Treated With Gentamicin 360mg IM Who Have a Negative Culture. Started Sep 2018; status: terminated.
02
Drugs
gentamicin
03
Conditions
Pharyngeal gonorrhea (PGC)
Beyond the preview
Go deeper on NCT03632109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03632109.